TJ 100

Drug Profile

TJ 100

Alternative Names: Dai-kencho-to; Dai-kenchu-to; TU-100

Latest Information Update: 05 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Tsumura
  • Class Anti-inflammatories; Herbal medicines; Laxatives
  • Mechanism of Action Acetylcholine stimulants; Motilin stimulants; Serotonin 3 receptor agonists; Serotonin 4 receptor agonists; Substance P stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Irritable bowel syndrome; Postoperative ileus
  • Phase III Constipation
  • Phase II Crohn's disease

Most Recent Events

  • 01 May 2017 Tsumara completes a phase II trial for Postoperative ileus in USA (NCT02232893)
  • 15 Dec 2016 Biomarkers information updated
  • 29 Nov 2016 Tsumura completes a phase-III trial in Constipation in Japan (PO)(UMIN000008070)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top